DBV Technologies (NASDAQ:DBVT) Shares Gap Down – Time to Sell?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) gapped down before the market opened on Tuesday . The stock had previously closed at $18.29, but opened at $17.50. DBV Technologies shares last traded at $18.1570, with a volume of 43,116 shares traded.

Wall Street Analyst Weigh In

Several research firms have weighed in on DBVT. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective (up previously from $35.00) on shares of DBV Technologies in a research note on Wednesday. Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. HC Wainwright set a $40.00 target price on DBV Technologies in a research report on Thursday. Finally, Zacks Research raised DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Trading Down 4.6%

The company’s fifty day moving average is $15.23 and its 200-day moving average is $11.72. The firm has a market capitalization of $864.16 million, a P/E ratio of -4.16 and a beta of -1.10.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Millennium Management LLC boosted its holdings in DBV Technologies by 26.1% in the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after purchasing an additional 69,849 shares during the period. Citadel Advisors LLC acquired a new position in shares of DBV Technologies during the third quarter valued at about $220,000. Two Sigma Investments LP acquired a new position in shares of DBV Technologies during the third quarter valued at about $167,000. DLD Asset Management LP bought a new stake in shares of DBV Technologies in the third quarter valued at about $250,000. Finally, Artisan Partners Limited Partnership acquired a new stake in shares of DBV Technologies during the 3rd quarter worth approximately $519,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.